The University of Southampton
University of Southampton Institutional Repository

Comparison of antifibrotic availability for patients on the BTS IPF registry using existing and new prescribing criteria

Comparison of antifibrotic availability for patients on the BTS IPF registry using existing and new prescribing criteria
Comparison of antifibrotic availability for patients on the BTS IPF registry using existing and new prescribing criteria
Antifibrotic prescribing is changing significantly in the UK with new National Institute for Health and Care Excellence (NICE) guidelines for nintedanib prescribing in IPF set to be published in February 2023 (NICE, 2022). There are also inconsistencies in prescribing between patients with IPF and PF-ILD.

Our aim was to evaluate discrepancies in anti-fibrotic availability for patients on a national IPF registry using current, future and PF-ILD UK prescribing criteria.

Permission was obtained from the British Thoracic Society (BTS) Information Governance Committee to access FVC readings for patients with IPF on the National BTS ILD registry. As of December 2022, 3,652 patients were on the registry. Of these, 987 had serial FVC readings. We compared anti-fibrotic eligibility in this cohort using three UK prescribing criteria; current NICE guidelines (FVC 50-80% predicted), new NICE guidelines (FVC ≥50%) and PF-ILD criteria (≥10% FVC decline in a 2 year period).

Based on first FVC results, 60.5% (n=2185) of patients met current NICE guidelines for antifibrotics. Using new NICE guidelines, 97.5% (n=3519) would be eligible, an increase of 36.9%. Of the patients with serial FVC results who were ineligible for antifibrotics based on current NICE guidelines, 109 met PF-ILD criteria for nintedanib (median FVC drop of 13.9% over 298 days).

There is significant variation in antifibrotic availability for patients depending on the prescribing criteria applied. Changes to current UK prescribing guidelines in IPF will significantly increase anti-fibrotic availability. This data highlights the need to upscale current UK ILD services.
0903-1936
Naftel, Jennifer
df89fbd1-7ef2-4ee7-9e2c-3f1878bc8d85
Kinsella, Emma
30eac61b-7265-4795-8f3e-f7e59d26a875
Wood, Nicola
647ea451-0a77-4f70-89d3-adf85590a4e5
Fletcher, Sophie
d05721e8-8943-4f13-a1f5-4ba183741c89
Naftel, Jennifer
df89fbd1-7ef2-4ee7-9e2c-3f1878bc8d85
Kinsella, Emma
30eac61b-7265-4795-8f3e-f7e59d26a875
Wood, Nicola
647ea451-0a77-4f70-89d3-adf85590a4e5
Fletcher, Sophie
d05721e8-8943-4f13-a1f5-4ba183741c89

Naftel, Jennifer, Kinsella, Emma, Wood, Nicola and Fletcher, Sophie (2023) Comparison of antifibrotic availability for patients on the BTS IPF registry using existing and new prescribing criteria. European Respiratory Journal, 62 (Suppl 67), [PA2886]. (doi:10.1183/13993003.congress-2023.PA2886).

Record type: Meeting abstract

Abstract

Antifibrotic prescribing is changing significantly in the UK with new National Institute for Health and Care Excellence (NICE) guidelines for nintedanib prescribing in IPF set to be published in February 2023 (NICE, 2022). There are also inconsistencies in prescribing between patients with IPF and PF-ILD.

Our aim was to evaluate discrepancies in anti-fibrotic availability for patients on a national IPF registry using current, future and PF-ILD UK prescribing criteria.

Permission was obtained from the British Thoracic Society (BTS) Information Governance Committee to access FVC readings for patients with IPF on the National BTS ILD registry. As of December 2022, 3,652 patients were on the registry. Of these, 987 had serial FVC readings. We compared anti-fibrotic eligibility in this cohort using three UK prescribing criteria; current NICE guidelines (FVC 50-80% predicted), new NICE guidelines (FVC ≥50%) and PF-ILD criteria (≥10% FVC decline in a 2 year period).

Based on first FVC results, 60.5% (n=2185) of patients met current NICE guidelines for antifibrotics. Using new NICE guidelines, 97.5% (n=3519) would be eligible, an increase of 36.9%. Of the patients with serial FVC results who were ineligible for antifibrotics based on current NICE guidelines, 109 met PF-ILD criteria for nintedanib (median FVC drop of 13.9% over 298 days).

There is significant variation in antifibrotic availability for patients depending on the prescribing criteria applied. Changes to current UK prescribing guidelines in IPF will significantly increase anti-fibrotic availability. This data highlights the need to upscale current UK ILD services.

This record has no associated files available for download.

More information

Published date: 27 October 2023

Identifiers

Local EPrints ID: 486032
URI: http://eprints.soton.ac.uk/id/eprint/486032
ISSN: 0903-1936
PURE UUID: 90e3eb2d-5ac1-4ac8-ba01-15567bac4db8

Catalogue record

Date deposited: 05 Jan 2024 18:13
Last modified: 17 Mar 2024 06:42

Export record

Altmetrics

Contributors

Author: Jennifer Naftel
Author: Emma Kinsella
Author: Nicola Wood
Author: Sophie Fletcher

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×